Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01256775|
Recruitment Status : Completed
First Posted : December 9, 2010
Last Update Posted : January 19, 2011
Peripheral arterial disease (PAD) is almost invariably associated with a generalized atherosclerotic involvement of the arterial tree and endothelial dysfunction. Previous short term studies showed improvement of vascular reactivity and walking capacity in PAD patients by measures aimed at restoring Nitric Oxide (NO) production. NO is also known to prevent the progression of atherosclerosis. We wished to assess whether the prolonged administration of a NO-donating agent (NCX 4016) improves the functional capacity of PAD patients and affects the progression of atherosclerosis as assessed by carotid intima-media thickness (IMT).
Four hundred forty two patients with stable intermittent claudication were enrolled in a prospective, double blind, placebo-controlled study and randomized to either NCX 4016 800mg bid or its placebo for 6 months. The primary study outcome was the absolute claudication distance (ACD) on a constant treadmill test (10% incline, 3km/hr); main secondary end-point was the change of the mean far-wall right common carotid artery IMT.
|Condition or disease||Intervention/treatment||Phase|
|Intermittent Claudication||Drug: NCX-4016 Drug: NCX4016 placebo||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||442 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Multicenter, Double-blind, Randomized, Parallel Group Study to Assess the Effect of NCX4016 vs Placebo on Walking Distance in Patients With Peripheral Arterial Occlusive Disease at Leriche-Fontaine Stage II|
|Study Start Date :||September 2003|
|Primary Completion Date :||April 2005|
|Study Completion Date :||April 2005|
Placebo Comparator: NCX4016 placebo
NCX4016 placebo b.i.d for 6 months
Drug: NCX4016 placebo
NCX4016 placebo b.i.d. for 6 months
Active Comparator: NCX4016
ncx4016,800 mg b.i.d., on top of aspirin 100 mg o.d.
NCX4016 800 mg b.i.d. for 6 months on top of aspirin 100 mg o.d.
- maximal walking distance evaluated by a constant treadmill test [ Time Frame: baseline ]
- maximal walking distance evaluated by a constant treadmill test [ Time Frame: 6 months ]
- pain-free walking distance [ Time Frame: baseline, 1-3-6 months ]
- assessment of carotid artery IMT [ Time Frame: baseline and 6 month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01256775
|Ospedale di Perugia|
|Perugia, Italy, 06126|
|Principal Investigator:||Paolo Gresele, M.D., Ph.D.||University of Perugia, Italy|